Alnylam Pharmaceuticals
ALNY
496 hedge funds and large institutions have $26.7B invested in Alnylam Pharmaceuticals in 2022 Q3 according to their latest regulatory filings, with 118 funds opening new positions, 170 increasing their positions, 151 reducing their positions, and 39 closing their positions.
203% more first-time investments, than exits
New positions opened: 118 | Existing positions closed: 39
83% more funds holding in top 10
Funds holding in top 10: 6 → 11 (+5)
62% more capital invested
Capital invested by funds: $16.5B → $26.7B (+$10.2B)
18% more funds holding
Funds holding: 421 → 496 (+75)
17.7% more ownership
Funds ownership: 93.9% → 111.6% (+18%)
13% more repeat investments, than reductions
Existing positions increased: 170 | Existing positions reduced: 151
11% more call options, than puts
Call options by funds: $298M | Put options by funds: $270M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
N
Nuveen
Charlotte,
North Carolina
|
+$3.11B |
| 2 |
Capital World Investors
Los Angeles,
California
|
+$698M |
| 3 |
Janus Henderson Group
London,
United Kingdom
|
+$133M |
| 4 |
Holocene Advisors
New York
|
+$123M |
| 5 |
Invesco
Atlanta,
Georgia
|
+$109M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$625M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$262M |
| 3 |
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
|
-$142M |
| 4 |
AllianceBernstein
Nashville,
Tennessee
|
-$114M |
| 5 |
AG
Artal Group
Luxembourg
|
-$87.5M |
ALNY Hedge Fund Activity: Q3 2022 in Review
496 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Alnylam Pharmaceuticals (ALNY) for Q3 2022, worth a combined $26.7B — up 62% from $16.5B a quarter earlier.
Buyers outnumbered sellers: 118 funds opened new ALNY positions and 39 closed out — a net gain of 79 holders — while 170 added to existing stakes and 151 trimmed.
The largest buyer was Nuveen, adding an estimated $3.11B. The largest seller was T. Rowe Price Associates, cutting an estimated $625M.
- 496 institutional investors held Alnylam Pharmaceuticals (ALNY) as of Q3 2022, up from 421 in Q2 2022.
- Funds reported $26.7B of Alnylam Pharmaceuticals stock for Q3 2022, up 62% quarter-over-quarter.
- 118 funds opened new Alnylam Pharmaceuticals positions in Q3 2022 and 39 closed out, a net change of +79 holders.
- The largest Alnylam Pharmaceuticals buyer in Q3 2022 was Nuveen, an estimated $3.11B added.
- The largest Alnylam Pharmaceuticals seller in Q3 2022 was T. Rowe Price Associates, an estimated $625M sold.
Based on aggregated 13F filings for Q3 2022.